Kazia Therapeutics Limited (NASDAQ: KZIA) announced plans to expand enrollment in its ongoing Phase 1b clinical trial of paxalisib in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE